Health Stocks Rising on Big Volume (JNJ, GILD)

Los Angelas, CA -- (SBWIRE) -- 03/05/2013 -- Johnson & Johnson’s (NYSE:JNJ) Janssen Research & Development LLC reported that the US Food and Drug Administration once more refused the acceptance of its blood thinner Xarelto for patients with a heart problem called as acute coronary syndrome.

The FDA had formerly refused Xarelto for this use in June due to doubts regarding life-threatening bleeding.

Janssen reported that it is assessing the second complete response letter and would react to the agency’s questions.

At the current trading session, Johnson & Johnson shares gained +0.52% to $77.60 while The Stock traded within the range of $77.44 – $77.67. In the past year, the stock has traded within a range of $61.71 – $77.67. The current session’s volume of 949,528.00 million shares is down from the average daily trading volume of 9.89 million shares.

An experimental drug combination from Gilead Sciences Inc. (GILD), Medivir AB (MVIRB) and Johnson & Johnson (JNJ) removed the virus that results in hepatitis C in patients with the liver disease in a study.

The trial’s 80 patients, who had tried and failed other treatments, received a two-drug combination of Medivir’s simeprevir and Gilead’s sofosbuvir, as per reported by a research presented at the Conference on Retroviruses and Opportunistic Infections on Tuesday in Atlanta.

The patients received the mixture for 12 or 24 weeks, with and without the antiviral ribavirin, researchers added.

Gilead Sciences, Inc (NASDAQ:GILD) shares are up +2.50% to $44.97 while the stock is traded within the range of $44.35 – $45.03 in the current trading session. In the last 12 months the shares have traded between $22.40 and $45.03. The current session’s volume of 1.73 million shares is lower than their average daily trading volume of 9.46 million shares.

Find Out Where JNJ, GILD Is Headed Next. CLICK HERE

Disclaimer
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com